Core Viewpoint - Qianjin Pharmaceutical (600479.SH) has received drug registration certificates for Dydrogesterone tablets, Baricitinib tablets (4mg, 2mg), and Dapagliflozin tablets (5mg, 10mg) from the National Medical Products Administration, indicating successful consistency evaluation and enhancing the company's product pipeline, which is beneficial for sustainable development [1] Group 1 - Qianjin Pharmaceutical and its subsidiary, Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd., have obtained drug registration certificates for three new products [1] - The approval of Dydrogesterone tablets, Baricitinib tablets, and Dapagliflozin tablets signifies that these products have passed the consistency evaluation [1] - The addition of these products to the company's portfolio is expected to enrich its product pipeline and support sustainable growth [1]

Group 1 - The core point of the article is that Qianjin Pharmaceutical has received drug registration certificates for three products from the National Medical Products Administration, indicating a significant regulatory approval milestone for the company [1] Group 2 - Qianjin Pharmaceutical and its subsidiary, Hunan Qianjin Xiangjiang Pharmaceutical, received approval for Dydrogesterone tablets, Baricitinib tablets, and Dapagliflozin tablets [1] - The approval of these drugs may enhance the company's product portfolio and market competitiveness in the pharmaceutical industry [1]

Core Viewpoint - Qianjin Pharmaceutical (600479.SH) and its subsidiary Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. have received drug registration certificates from the National Medical Products Administration for Dydrogesterone tablets, Baricitinib tablets (4mg, 2mg), and Dapagliflozin tablets (5mg, 10mg) [1] Group 1: Drug Approvals - The company has obtained approval for Dydrogesterone, a synthetic progestogen used for treating diseases caused by endogenous progesterone deficiency and for luteal support in assisted reproductive technology [1] - Baricitinib is a Janus kinase (JAK) inhibitor that blocks the activity of one or more members of the JAK kinase family, thereby inhibiting pathways that activate inflammation, developed in collaboration with Eli Lilly and Incyte [1] - Dapagliflozin is indicated for the treatment of type 2 diabetes [1]

证券代码：600479 证券简称：千金药业 公告编号：2026-001 株洲千金药业股份有限公司 关于公司及子公司获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，株洲千金药业股份有限公司（以下简称"公司"）及其下属子公司湖 南千金湘江药业股份有限公司（以下简称"千金湘江药业"）分别收到国家药品 监督管理局核准签发的地屈孕酮片、巴瑞替尼片（4mg、2mg）与达格列净片（5mg、 10mg）的《药品注册证书》。现将相关情况公告如下： 一、药品基本信息 （一）地屈孕酮片 药品名称：地屈孕酮片 剂型：片剂 规格：10mg 注册分类：化学药品 4 类 药品批准文号：国药准字 H20256508 药品上市许可持有人：株洲千金药业股份有限公司 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。质量标准、说明书、 标签及生产工艺照所附执行。药品生产企业应当符合药品生产质量管理规范要求 方可生产销售。 （二）巴瑞替尼片 药品名称：巴瑞替尼片 规格 ...

Core Viewpoint - Qianjin Pharmaceutical (600479.SH) has received drug registration certificates for Dydrogesterone tablets, Baricitinib tablets (4mg, 2mg), and Dapagliflozin tablets (5mg, 10mg) from the National Medical Products Administration, indicating successful consistency evaluation and enhancing the company's product pipeline, which is beneficial for sustainable development [1][1][1] Group 1 - Qianjin Pharmaceutical and its subsidiary, Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd., have obtained drug registration certificates for three new products [1] - The approval of Dydrogesterone tablets, Baricitinib tablets, and Dapagliflozin tablets signifies the company's successful compliance with consistency evaluation [1] - The addition of these products to the company's portfolio is expected to contribute positively to its sustainable growth [1]

Core Viewpoint - Qianjin Pharmaceutical (600479) has received approval from the National Medical Products Administration for the registration of three new drugs, indicating a significant advancement in its product portfolio and potential market opportunities [1] Group 1: Drug Approvals - Qianjin Pharmaceutical and its subsidiary, Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd., have received drug registration certificates for Dydrogesterone tablets, Baricitinib tablets (4mg, 2mg), and Dapagliflozin tablets (5mg, 10mg) [1] - Dydrogesterone tablets are indicated for the treatment of diseases caused by endogenous progesterone deficiency and for luteal support in assisted reproductive technology [1] - Baricitinib tablets are a Janus kinase (JAK) inhibitor that can block the activity of one or more members of the JAK kinase family, thereby inhibiting pathways that activate inflammation [1] - Dapagliflozin tablets are used for the treatment of type 2 diabetes [1]

Core Viewpoint - Qianjin Pharmaceutical (600479.SH) has received approval from the National Medical Products Administration for the registration of Dydrogesterone tablets, Baricitinib tablets (4mg, 2mg), and Dapagliflozin tablets (5mg, 10mg), which will enhance the company's product pipeline and support sustainable development [1] Group 1 - The approval of these drugs will enrich the company's product offerings [1] - The new products are expected to contribute positively to the company's growth and sustainability [1] - There are uncertainties related to drug production and sales due to policy and market environment factors [1]

Core Points - The Ministry of Industry and Information Technology of China has announced the public listing of the 2025 Consumer Brand List, which includes six brands from Hunan Province: Jiu Zhi Tang, Sheng De Xi, Anhua Black Tea, Xiangtan Lotus Seed, Nan County Rice Shrimp, and Qian Jin [1][22]. Group 1: Announcement Details - The announcement is based on the notification from the Ministry of Industry and Information Technology regarding the collection of consumer brands for 2025 [1]. - The public listing period is from January 5, 2026, to January 9, 2026, allowing for public feedback [1]. Group 2: Brand Listings - Six brands from Hunan Province are proposed for inclusion in the 2025 Consumer Brand List: - Jiu Zhi Tang (九芝堂) - Sheng De Xi (圣得西) - Anhua Black Tea (安化黑茶) - Xiangtan Lotus Seed (湘潭湘莲) - Nan County Rice Shrimp (南县稻虾米) - Qian Jin (千金) [1][22].

证券日报网讯12月30日，千金药业（600479）在互动平台回答投资者提问时表示，公司一直重视市值管 理工作，上市以来持续保持高比例分红，以实际行动回报股东。公司已制定中长期战略规划，目前正在 坚定落实战略举措，努力以更好的业绩回报投资者。二级市场股价受宏观经济、行业周期等多因素影 响，请投资者理性对待。 ...

Group 1 - The core viewpoint of the article highlights that Qianjin Pharmaceutical (600479) is implementing a digital transformation strategy across its entire value chain, aiming to reduce costs and improve efficiency [1] - The company's AI capabilities are being applied in various areas including research project initiation, production scheduling, procurement sourcing, decision-making for bulk medicinal materials, marketing knowledge assistance, and AI training [1] - The recent acquisition of minority shareholder rights in two companies is a significant step in executing the company's medium to long-term strategic plan, which is expected to enhance profitability and increase net profit attributable to the parent company [1] Group 2 - Qianjin Pharmacy currently operates approximately 1,800 stores, with a notable year-on-year increase in sales of influenza-related medications [1]